Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

116,989 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial.
Yao H, Yan M, Tong Z, Wu X, Ryu MH, Park JJ, Kim JH, Zhong Y, Zhao Y, Voskoboynik M, Yin Y, Liu K, Kaubisch A, Liu C, Zhang J, Wang S, Im SA, Ganju V, Barve M, Li H, Ye C, Roy AC, Bai LY, Yen CJ, Gu S, Lin YC, Wu L, Bao L, Zhao K, Shen Y, Rong S, Zhu X, Song E. Yao H, et al. Among authors: wang s. J Clin Oncol. 2024 Oct 10;42(29):3453-3465. doi: 10.1200/JCO.23.02044. Epub 2024 Jun 20. J Clin Oncol. 2024. PMID: 38900984 Clinical Trial.
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study.
Xu B, Sun T, Shi Y, Cui J, Yin Y, Ouyang Q, Liu Q, Zhang Q, Chen Y, Wang S, Wang X, Tong Z, Zhong Y, Wang J, Yan M, Yan X, Wang C, Feng J, Wang X, Hu G, Cheng Y, Ge R, Zhu Z, Zhang W, Shao Z. Xu B, et al. Among authors: wang x, wang j, wang s, wang c. Breast Cancer Res Treat. 2023 Feb;197(3):489-501. doi: 10.1007/s10549-022-06785-z. Epub 2022 Dec 2. Breast Cancer Res Treat. 2023. PMID: 36459284 Free PMC article. Clinical Trial.
Comparison of neoadjuvant chemotherapy response and prognosis among pegylated liposomal doxorubicin, epirubicin and pirarubicin in HR ⩽ 10%/HER2-negative breast cancer: an exploratory real-world multicentre cohort study.
Hong Y, Peng J, Chen Q, Zhou Q, Xu F, Yao J, Zou Q, Yuan L, Li L, Long Q, Liao L, Liu M, Liu X, Zhang D, Wang S, Yi W. Hong Y, et al. Among authors: wang s. Ther Adv Med Oncol. 2024 Sep 23;16:17588359241279695. doi: 10.1177/17588359241279695. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39346118 Free PMC article.
Comparison of neoadjuvant chemotherapy response and prognosis between HR-low/HER2-negative BC and TNBC: an exploratory real-world multicentre cohort study.
Peng J, Hong Y, Chen Q, Xu F, Zhang D, Yao J, Zou Q, Yuan L, Li L, Long Q, Liao L, Liu M, Liu X, Wang S, Yi W. Peng J, et al. Among authors: wang s. Front Endocrinol (Lausanne). 2024 Mar 19;15:1347762. doi: 10.3389/fendo.2024.1347762. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38567311 Free PMC article.
Efficacy and safety of neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy regimen in Chinese patients with HER2-positive early breast cancer: a real-world retrospective multi-center cohort study.
Zhou M, Wang S, Wan N, Yuan S, Hu X, Zhou W, Qing B, Liu M, Sun W, Fan P, Wang J, Cao H, Xu H, Dai B, Tang P, Qian L, Zhao X, Xiao J, Zhou H, Hu J, Ding L, Tripodi D, Zdenkowski N, O'Keefe TJ, Sanchez AM, Chen L, Zhang P, Xu F. Zhou M, et al. Among authors: wang j, wang s. Ann Transl Med. 2022 Dec;10(24):1387. doi: 10.21037/atm-22-6054. Ann Transl Med. 2022. PMID: 36660637 Free PMC article.
116,989 results
You have reached the last available page of results. Please see the User Guide for more information.